Triple Agonist

A compound class that simultaneously activates three metabolic hormone receptors: the GLP-1 receptor, GIP receptor, and glucagon receptor. Retatrutide (LY3437943) by Eli Lilly is the lead Phase 3 compound in this class. Adding glucagon receptor agonism to dual GLP-1/GIP activation increases hepatic glucose output suppression, lipolysis in adipose tissue, and resting energy expenditure through thermogenesis — mechanisms that may produce greater weight loss than dual agonists while maintaining similar tolerability profiles.